Cempra Pharmaceuticals
Cempra develops novel, well-differentiated antibiotics to meet critical unmet medical needs. Two lead products, both in clinical-stage development, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and the community.
Learn More
News and Events
Cempra Pharmaceutical's Cem-101 Demonstrates Potent Anti-Inflammatory Activity, Compared To Other Macrolide Antibiotics, In An Inflammation Cell Model At The American Thoracic Society 2010 International Conference
Cempra Pharmaceuticals today announced the results from two poster presentations on its novel antibiotic CEM-101, a next-generation macrolide, at the American Thoracic Society 2010 International Conference, May 14 to 19, 2010, in New Orleans...
Cempra Pharmaceuticals Names Mark W. Hahn as Executive Vice President and Chief Financial Officer
Cempra Pharmaceuticals Inc. today announced the appointment of Mark W. Hahn as executive vice president and chief financial officer...
View All [+]
Quick Links